Compare ARK Genomic Revolution ETF (ARKG) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nokia Corp — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Nokia Corp trades at $12.38 (market cap $69.26B). The key difference: Nokia Corp pays a 1.32% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Nokia Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | NOK | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $16.83 |
52-Week Low | $23.09 | $4.05 |
Market Cap | — | $69.26B |
Enterprise Value | — | $66.08B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Nokia (NOK) trades at $12.43, down 3.72% amid a broader market pullback, despite strong year-to-date gains driven by AI infrastructure optimism. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a $18.00 consensus price target. Recent earnings have been mixed, with a Q1 2026 miss after previous beats, while fundamentals indicate modest profitability with a 3.98% net margin and elevated P/E of 78.03. The company's pivot to AI networking, including partnerships with Nvidia and Orange Belgium, fuels growth expectations.
Outlook: NOK's AI-driven transformation offers upside potential, but high valuation and execution risks warrant caution. Near-term performance hinges on Q2 2026 earnings due July 23, which could validate AI revenue streams. Risks include competitive pressures and reliance on telecom spending cycles. Analyst bullishness suggests 45% upside to target, though technical weakness may persist short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
